Evaluation of Diagnostic Accuracy of [68Ga]Ga-PSMA-11 PET/CT in Primary Staging of Intermediate and High Risk Prostatic Cancer in Men Newly Diagnosed

Inclusion Criteria: I. Patients with histo-pathological confirmation of PCa with intermediate or high-risk disease according to 2019 Prostate Cancer EAU Guidelines Risk Group Stratification (see Study Population paragraph) II. Patients with conventional imaging mpMRI (with or without CT of the lower abdomen and Bone scan) performed as baseline in primary PCa staging according to 2019 Prostate Cancer EAU Guidelines III. Age \>18 years/old IV. Ability to provide written informed consent Exclusion Criteria: I. Contra-indication for PET/CT scan: Patients not capable of getting PET study due to weight, claustrophobia, or inability to lay still for the duration of the exam II. Impaired renal function III. Impaired liver function: AST or ALT \> 2.5 x ULN IV. Patients unable to understand the purpose of the study V. Medical history of allergic reactions or hypersensitivity to \[68Ga\] Ga-PSMA-11 as well as to any excipient or component of the experimental medicinal product VI. Having partecipated in clinical trial in which the experimental intervention was administered within 30 days (or 5 half-life) from administration the endovenous solution of \[68Ga\]Ga-PSMA-11